Taurine Eye Drops May Prevent the Progression of Cataract

NCT06639711 | Active Not Recruiting Phase 1

• 1 other identifier: UOANBAR-170
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract. This study could answer:

• Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
• The acceptance/ compliance of participants to taurine-containing eye drops.
• Could long-term use of taurine-containing eye drops cause adverse effect(s)? Participants will:
• Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
• Visit eye clinic every 3 months for assessment and visual examination.
• Keep notes for their symptoms and their adherence to treatment.

Conditions

Cataract

Outcome Measures

Primary Outcomes (1)

• Visual Acuity

  1 Year

Study Arms (1)

Application of Taurine-containing Eye Drops

EXPERIMENTAL

Drug: Taurine

Interventions

Taurine DRUG

Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year

Also known as: VIZILOTIN Eye Drops

Application of Taurine-containing Eye Drops

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The presence of grade I or II senile cataract on one or two eyes.

You may not qualify if:

• clinical signs of glaucoma
• history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
• history of iritis, retinal crystalline deposits, or optic nerve disease
• visually significant fundus pathology

Sponsors & Collaborators

• University Of Anbar: lead

Study Sites (1)

Al-Nahrain Eye Clinics

Ramadi, Al-Anbar Governorate, 31001, Iraq

Location

MeSH Terms

Conditions

Cataract

Interventions

Taurine

Condition Hierarchy (Ancestors)

Lens Diseases; Eye Diseases

Intervention Hierarchy (Ancestors)

Alkanesulfonic Acids; Alkanes; Hydrocarbons, Acyclic; Hydrocarbons; Organic Chemicals; Sulfonic Acids; Sulfur Acids; Sulfur Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Asst. Prof. Dr. Atheer Zgair

Model Details: single-arm pre-post intervention study

Study Record Dates

• First Submitted: October 10, 2024
• First Posted: October 15, 2024
• Study Start: July 10, 2023
• Primary Completion: December 20, 2024
• Study Completion: December 20, 2024
• Last Updated: December 9, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

IR (1)